Navigation Links
Mega-Brand Success: Effective Market Strategy and Tactics
Date:6/10/2008

CHAPEL HILL, N.C., June 10 /PRNewswire/ -- Pharmaceutical companies can literally add -- or subtract -- billions of dollars in the lifetime cash flows of potential mega-brands. Research and development groups no longer singularly drive the value of a new product. Sales and Marketing teams also have a place at the head of the table at which market success is determined.

Best Practices, LLC's white paper "Launching a Blockbuster: Making and Marketing Mega-Brands" (available at http://www.best-in-class.com/cr217.htm) addresses how savvy long-term marketing strategy and tactics can help shape a drug's true market potential and can dramatically increase its lifetime economic value.

For more information on how Best Practices, LLC can work with you to answer your pressing Brand Launch questions, visit http://www.best-in-class.com or contact Cameron Tew at (919) 403-0251, ext. 246 or ctew@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call (919) 403-0251 or visit http://www.best-in-class.com .


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems
2. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
3. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
4. Oncothyreon announces effectiveness of shelf registration statement
5. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
6. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
7. Evotecs Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
8. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2University of California, San Francisco, researcher receives ASBMB-Merck Award 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 1CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 3CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 4CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 5CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 6CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 7CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 8CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 9CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 10CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 11CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 12CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 13CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 14CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 15Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 1Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 2Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 1Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 2Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 4Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 5Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 6Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 7Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 8Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 9Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 10Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 11Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 12Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 13Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 14Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 15